University of Texas Texas AM Investment Management Co. Buys Shares of 165,020 Pfizer Inc. $PFE

University of Texas Texas AM Investment Management Co. purchased a new position in Pfizer Inc. (NYSE:PFE) during the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 165,020 shares of the biopharmaceutical company’s stock, valued at approximately $3,974,000.

A number of other institutional investors have also made changes to their positions in PFE. Godfrey Financial Associates Inc. acquired a new position in Pfizer in the fourth quarter valued at about $26,000. Keb Asset Management LLC acquired a new position in Pfizer during the second quarter valued at approximately $26,000. HFM Investment Advisors LLC increased its stake in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares in the last quarter. Evolution Wealth Management Inc. raised its stake in Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 566 shares during the period. Finally, Abound Financial LLC bought a new position in Pfizer during the fourth quarter worth about $31,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of NYSE PFE opened at $26.88 on Tuesday. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $28.75. The stock has a 50 day moving average of $25.15 and a 200-day moving average of $26.20. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $153.21 billion, a P/E ratio of 35.37 and a beta of 0.34.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the firm posted $0.78 EPS. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Analyst Upgrades and Downgrades

PFE has been the subject of several recent analyst reports. BMO Capital Markets lowered their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and reduced their price target for the company from $32.00 to $28.00 in a report on Monday, July 6th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Citigroup increased their target price on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. Finally, Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a research report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $28.28.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.